An ear­ly-stage fail high­lights on­go­ing ALS drug de­vel­op­ment chal­lenges, de­spite re­cent Bio­gen OK

A Take­da part­ner re­port­ed an ear­ly-stage ALS tri­al fail­ure Tues­day morn­ing and opt­ed to dis­con­tin­ue the pro­gram en­tire­ly, serv­ing as a re­minder that de­spite two …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER